Drug Trial Radar · NCT03378531
A Study of AEB1102 (Pegzilarginase) in Patients With Arginase 1 Deficiency
Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14
Actual
Start
Dec 7, 2017
Primary completion
Dec 15, 2022
Study completion Dec 15, 2022
Sponsor
- Lead sponsor
- Immedica Pharma ABIndustry
- Sponsor type
- Industry
- Collaborators
- Aeglea Biotherapeutics
- First posted
- Dec 20, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety, tolerability, and efficacy of long-term intravenous and subcutaneous administration of pegzilarginase for the treatment of pediatric and adult patients with ARG1-D who complete Study CAEB1102-101A.
Conditions
- Arginase I Deficiency
- Hyperargininemia
Interventions
AEB1102Drug
modified human arginase I
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-related Adverse EventsTime frame: From start of study up to 262 weeks
- Number of Participants With Anti-pegzilarginase and Anti-PEG AntibodiesTime frame: From start of study up to 262 weeks
Locations
7 sites in 4 countries. Site status is shown where the registry gives one.
Stanford University School of Medicine
Stanford, California
University of Florida
Gainsville, Florida
Icahn School of Medicine at Mount Sinai
New York, New York
UTSW
Dallas, Texas
The Hospital for Sick Children
Toronto, Ontario, Canada
Centro Hospitalar S. Joao
Porto, Portugal
Great Ormond Street Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.